What is the primary objective of FDA 21 CFR Part 11?

The primary objective of FDA 21 CFR Part 11 is to establish criteria under which the Agency considers electronic records and electronic signatures trustworthy, reliable, and equivalent to paper records and handwritten signatures executed on paper (§11.1(a)). This equivalency enables electronic methods while ensuring authenticity, integrity, availability, and non-repudiation through controls like validation (§11.10(a)), secure audit trails (§11.10(e)), access limitations (§11.10(d)), and electronic signature requirements (§§11.50–11.300).

Who is legally or professionally required to comply with FDA 21 CFR Part 11?

FDA 21 CFR Part 11 applies to organizations using electronic records created, modified, maintained, archived, retrieved, or transmitted under predicate rules, or submitted electronically to FDA (§11.1(b)). It targets life sciences firms (pharma, biotech, devices) relying on electronic records in lieu of paper for regulated activities, or where electronic versions are relied upon even if paper exists; exclusions apply to certain food records (§11.1(f)–(p)) and paper records transmitted electronically.

Does FDA 21 CFR Part 11 require an external audit or third-party certification?

No, FDA 21 CFR Part 11 does not require external audits or third-party certification. Compliance is demonstrated through internal controls, validation, SOPs, and inspection readiness (§11.1(e)); FDA verifies during inspections, enforcing predicate rules and key provisions like access controls and signatures per 2003 guidance, without mandating accredited certification.

How often should an assessment for FDA 21 CFR Part 11 be performed?

FDA 21 CFR Part 11 does not prescribe a fixed frequency for assessments; organizations must perform risk-based periodic reviews tied to change control, system lifecycle, and predicate rules. The 2003 guidance supports ongoing evaluation via validation lifecycle, operational checks (§11.10(f)), and documentation controls (§11.10(k)), with reassessments triggered by changes, inspections, or risk updates.

What are the consequences of non-compliance with FDA 21 CFR Part 11?

Non-compliance with FDA 21 CFR Part 11 can result in FDA enforcement actions including Form 483 observations, warning letters, product holds, recalls, and fines under predicate rules. The 2003 guidance notes continued enforcement of access controls, signatures, and checks; failures often lead to data integrity violations, as in warning letters citing inadequate audit trails and investigations.

Can FDA 21 CFR Part 11 be mapped to other international frameworks?

Yes, FDA 21 CFR Part 11 control objectives such as audit trails, access controls, and signature linking align with frameworks like EU Annex 11, though direct mapping requires risk-based adaptation. The regulation focuses on equivalency (§11.1(a)); organizations document alignments for hybrid compliance, noting FDA's narrow scope and enforcement discretion.

What is the first step to begin implementing FDA 21 CFR Part 11?

The first step to implement FDA 21 CFR Part 11 is to establish a formal applicability framework mapping predicate rules to records and assessing business reliance on electronic versions. Per 2003 guidance, document scope decisions in SOPs (e.g., electronic in lieu of paper), classify systems as closed/open (§11.3), and prioritize risk-based controls.

What is the primary objective of MAS TRM?

MAS TRM's primary objective is to establish sound technology risk governance and cyber resilience through defence-in-depth controls preserving CIA of systems and data. Per the January 2021 Guidelines (Preface 1.4), financial institutions must implement proportional practices across governance (Section 3.1), risk frameworks (Section 4), secure SDLC (Sections 5-6), IT service management (Section 7), resilience (Section 8), cyber operations (Section 12), and assessments (Section 13), ensuring board-approved risk appetite and continuous improvement amid digital threats.

Who is legally or professionally required to comply with MAS TRM?

MAS TRM applies to all financial institutions supervised by MAS, including banks, insurers, capital market intermediaries, payment service providers, and fintech sandbox participants. Section 2 targets FIs with implementation proportional to risk, complexity, and service criticality (Section 2.2); boards and senior management bear accountability (Section 3.1), with appointed CIO/CISO roles (Section 3.1.3). Non-compliance risks supervisory actions like capital add-ons or operational restrictions.

Does MAS TRM require an external audit or third-party certification?

MAS TRM mandates an independent internal audit function but does not require external audits or third-party certification. Section 3.1.7 requires boards to ensure independent audit assesses TRM controls, governance, and risk management (Section 15); external penetration testing or managed services are expected for realism (Section 13.2), but certification (e.g., ISO) is optional for assurance.

How often should an assessment for MAS TRM be performed?

TRM assessments must occur regularly, with frequency commensurate to system criticality and exposure. Vulnerability assessments are ongoing (Section 13.1.1); Internet-facing systems require penetration testing at least annually or post-major changes (Section 13.2.4); DR plans reviewed annually (Section 8.2.2), policies updated for threats (Section 3.2.1), and risk frameworks reviewed periodically (Section 4.1.5).

What are the consequences of non-compliance with MAS TRM?

Non-compliance with MAS TRM risks supervisory enforcement, including fines, license conditions, revocations, and executive prohibitions. MAS considers TRM observance in supervision (Section 2.2); examples include significant regulatory capital add-ons for severe IT outages and CMS license revocation for governance failures, with personal liability for boards/senior management (Section 3.1).

Can MAS TRM be mapped to other international frameworks?

Yes, MAS TRM maps to frameworks like NIST CSF 2.0 and ISO 27001 via shared outcomes in governance, risk lifecycle, and controls. TRM's CIA focus aligns with NIST's Identify-Protect-Detect-Respond-Recover-Govern; Section 3.2.1 encourages industry standards/best practices. Use CSRR (NIST IR 8286) for ERM integration and ISO Annex A for control baselines.

What is the first step to begin implementing MAS TRM?

The first step is board approval of a technology risk appetite/tolerance statement and establishment of governance structures. Section 3.1.7 requires boards to approve appetite, ensure independent TRM/audit functions, and appoint CIO/CISO (Section 3.1.3); follow with asset inventory (Section 3.3) for proportional control design.

Standards Comparison

FDA 21 CFR Part 11 vs MAS TRM

FDA 21 CFR Part 11

Mandatory

1997

FDA regulation for trustworthy electronic records and signatures

MAS TRM

Mandatory

2021

Singapore guidelines for financial technology risk management

Quick Verdict

FDA 21 CFR Part 11 mandates electronic records/signatures equivalence for life sciences, ensuring data integrity via validation. MAS TRM guides financial firms on cyber resilience through governance and testing. Organizations adopt them for regulatory compliance and trustworthy digital operations.

Electronic Records

FDA 21 CFR Part 11

21 CFR Part 11: Electronic Records; Electronic Signatures

Cost

€€€€

Complexity

Medium

Implementation Time

18-24 months

Key Features

Establishes equivalency of electronic records to paper
Mandates secure, time-stamped audit trails
Requires unique, non-repudiable electronic signatures
Enforces closed/open system access controls
Demands risk-based system validation

Technology Risk Management

MAS TRM

MAS Technology Risk Management Guidelines

Cost

€€€€

Complexity

High

Implementation Time

12-18 months

Key Features

Board and senior management accountability
Proportionality based on risk and complexity
Third-party risk management requirements
Layered defence-in-depth cyber controls
Annual penetration testing for internet systems

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

FDA 21 CFR Part 11 Details

What It Is

FDA 21 CFR Part 11 is a U.S. regulation establishing criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate-rule records. The approach is risk-based, with narrow scope per 2003 FDA guidance emphasizing enforcement discretion for validation, audit trails, retention, and legacy systems while enforcing core controls.

Key Components

Subparts: General provisions, electronic records (closed/open systems), electronic signatures.
Core controls: validation (§11.10(a)), audit trails (§11.10(e)), access limits (§11.10(d)), operational/authority/device checks (§11.10(f)-(h)), training (§11.10(i)), signature policies (§11.10(j)), documentation (§11.10(k)).
Signature requirements: manifestation (§11.50), linking (§11.70), uniqueness (§11.100), multi-component (§11.200), ID/password controls (§11.300).
Compliance via risk-based validation, no formal certification but inspection readiness.

Why Organizations Use It

Mandated for electronic reliance in pharma, devices, biotech; mitigates enforcement risks like warning letters; ensures data integrity for quality decisions; enables paperless efficiency, faster inspections; builds regulator/partner trust.

Implementation Overview

Phased: scope predicate records, gap analysis, CSV (URS, IQ/OQ/PQ), vendor governance, SOPs/training, ongoing monitoring. Applies to life sciences globally under FDA jurisdiction; requires demonstrable controls for inspections.

MAS TRM Details

What It Is

MAS Technology Risk Management (TRM) Guidelines (January 2021) are supervisory guidelines issued by Singapore's Monetary Authority of Singapore (MAS) for financial institutions. They provide a principles-based framework focused on governance, cybersecurity, resilience, and third-party risks to preserve confidentiality, integrity, and availability (CIA) of systems and data. The risk-based approach emphasizes proportionality to an FI's complexity and risk profile.

Key Components

15 sections covering governance, risk frameworks, SDLC, IT service management, resilience, access controls, cryptography, cyber operations, assessments, and audit.
Synthesised into 12 core principles like board accountability, asset inventory, secure engineering, and layered defences.
No fixed controls; relies on continuous improvement and independent assurance.

Why Organizations Use It

Regulatory supervision: MAS evaluates observance in inspections, with enforcement risks (fines, sanctions).
Enhances resilience against cyber threats and digitalisation risks.
Builds stakeholder trust, enables innovation, supports ERM integration.

Implementation Overview

Phased: governance setup, asset inventory, control design, testing, monitoring.
Applies to MAS-supervised FIs (banks, insurers, fintechs); scalable by size.
No formal certification; demonstrated via audits, metrics, board reporting. (178 words)

Key Differences

Aspect	FDA 21 CFR Part 11	MAS TRM
Scope	Electronic records/signatures trustworthiness	Technology/cyber risk governance across finance
Industry	Life sciences, pharma, medical devices (US)	Financial institutions in Singapore
Nature	Mandatory US federal regulation	Supervisory guidelines with enforcement discretion
Testing	Risk-based system validation, audit trails	Annual pen testing, vulnerability assessments, DR tests
Penalties	Warning letters, seizures, injunctions	Fines, license revocation, executive prohibitions

Scope

FDA 21 CFR Part 11

Electronic records/signatures trustworthiness

MAS TRM

Technology/cyber risk governance across finance

Industry

FDA 21 CFR Part 11

Life sciences, pharma, medical devices (US)

MAS TRM

Financial institutions in Singapore

Nature

FDA 21 CFR Part 11

Mandatory US federal regulation

MAS TRM

Supervisory guidelines with enforcement discretion

Testing

FDA 21 CFR Part 11

Risk-based system validation, audit trails

MAS TRM

Annual pen testing, vulnerability assessments, DR tests

Penalties

FDA 21 CFR Part 11

Warning letters, seizures, injunctions

MAS TRM

Fines, license revocation, executive prohibitions

Frequently Asked Questions

Common questions about FDA 21 CFR Part 11 and MAS TRM

FDA 21 CFR Part 11 FAQ

MAS TRM FAQ

You Might also be Interested in These Articles...

ISO 27701 Standalone Certification in 2025: Debunking Myths and Navigating the New Reality

Debunk myths on ISO 27701 standalone certification post-2025. Clarify viability, accreditation bodies, ISO 27001 audit differences & procurement benefits. Guide

You Guide on how to Start Implementing NIST CSF in Your Organization

Master NIST CSF implementation in your organization with this detailed guide. Learn core functions, key steps, best practices, and tips for cybersecurity succes

CIS Controls v8.1 IG1 Ransomware-Resilience Sprint: A 30-60-90 Day Action Plan (With Evidence Checklist)

Tactical CIS Controls v8.1 IG1 playbook for ransomware resilience. 30-60-90 day sprint with tool-agnostic tasks, ownership & evidence checklists to prove progre

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how FDA 21 CFR Part 11 and MAS TRM compare against other standards

Other FDA 21 CFR Part 11 Comparisons

Other MAS TRM Comparisons

What It Is

Key Components

Subparts: General provisions, electronic records (closed/open systems), electronic signatures.

Core controls: validation (§11.10(a)), audit trails (§11.10(e)), access limits (§11.10(d)), operational/authority/device checks (§11.10(f)-(h)), training (§11.10(i)), signature policies (§11.10(j)), documentation (§11.10(k)).

Signature requirements: manifestation (§11.50), linking (§11.70), uniqueness (§11.100), multi-component (§11.200), ID/password controls (§11.300).

Compliance via risk-based validation, no formal certification but inspection readiness.

What It Is

Key Components

15 sections covering governance, risk frameworks, SDLC, IT service management, resilience, access controls, cryptography, cyber operations, assessments, and audit.

Synthesised into 12 core principles like board accountability, asset inventory, secure engineering, and layered defences.

No fixed controls; relies on continuous improvement and independent assurance.

Aspect

FDA 21 CFR Part 11

MAS TRM

Scope

Electronic records/signatures trustworthiness

Technology/cyber risk governance across finance

Industry

Life sciences, pharma, medical devices (US)

Financial institutions in Singapore

Nature

Mandatory US federal regulation

Supervisory guidelines with enforcement discretion

Testing

Risk-based system validation, audit trails

Annual pen testing, vulnerability assessments, DR tests

Penalties

Warning letters, seizures, injunctions

Fines, license revocation, executive prohibitions